DOCSLIB.ORG

Cerilliant Reference Standards Brochure

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cerilliant Reference Standards Brochure QUALITY FOR LIFE Certified Reference Materials for Clinical Testing Merck KGaA Certified Reference Materials (CRMs) are manufactured and certified to the highest industry standards including: • ISO Guide 34 • ISO 17025 • ISO 17043 • ISO 13485 • ISO 9001 • GMP The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada. Quality For Life Every test can impact a life Results are only as accurate as your reference Certified Reference Material Categories for Clinical Applications of Testosterone in Serum for • Amino Acids • Fatty Acids Clinical Research Applications • Analgesics • Hormones • Individual levels of testosterone in – Female stripped serum offered separately • Antibiotics – Male at concentrations ranging from – Neonatal 2 to 2,000 ng/dL • Anticancer Drugs – OH Vitamin D • Certified Reference Material grade • Antidepressants – Thyroid • Suitable for clinical research • Antiepileptics • Interference Mixes applications in the US by • Antifungals • Immunosuppressants liquid chromatography, mass spectrometry • Antipsychotics • Nicotine / Tobacco • Each level ready to use as • Antiretrovirals • Organic Acids a linearity standard or for • Bile Acids calibration verification • Biomarkers • Caffeine-related Drugs • NSAIDs • Cardiac Drugs • Vitamins (including A, • Catecholamines B, C, D, E, & K) To learn more, visit SigmaAldrich.com/standards 2 Product Description Cat. No. Product Description Cat. No. Amino Acids & Metabolites Antibiotics (Continued) Creatinine, Coming Soon C-164-1ML Moxifloxacin hydrochloride, 100 mg† B110255-100 † Creatinine-D3, Coming Soon C-165-1ML Ciprofloxacin-d8, 25 mg B130010-25 † Amino Acids Mix Solution, 2.5 mM of each 79248-5x2ML Moxifloxacin-d4 hydrochloride, 10 mg B130032-10 component Levofloxacin, 1.0 mg/mL L-038 Betaine, 50 mg 30056-50MG Metronidazole, 2.0 mg/mL M-183 Glycine, 100 mg 76524-100MG Chloramphenicol glucuronide, 1 mg† NMID714 L-Alanine, 100 mg 44526-100MG HMMNI (nitroimidazole metabolite), 50 mg† NMIP1296 L-Arginine monohydrochloride, 100 mg 90538-100MG Anticancer Drugs L-Asparagine, 100 mg 51363-100MG Busulfan, 1.0 mg/mL B-058 L-Aspartic acid, 100 mg 51572-100MG Busulfan-D8, 100 µg/mL B-068 L-Cysteine, 100 mg 95437-100MG 5-Fluorouracil, 50 mg 04541-50MG L-Cystine, 100 mg 49603-100MG Carboplatin, 250 mg† B110107-250 L-Glutamic acid, 100 mg 95436-100MG † Carboplatin-d6, 5 mg B130108-5 L-Glutamine, 100 mg 76523-100MG † Ifosfamide-d4, 10 mg B130323-10 L-Histidine, 100 mg 73767-100MG Methotrexate-D3, 100 µg/mL M-153 L-Isoleucine, 100 mg 56241-100MG Methotrexate, 1.0 mg/mL M-136 L-Leucine, 100 mg 76526-100MG Anticonvulsants/Antiepileptics L-Lysine monohydrochloride, 100 mg 67448-100MG N-Acetylretigabine, 100 µg/mL A-105 L-Methionine, 100 mg 39496-100MG Brivaracetam-D3, Coming Soon B-063-1ML L-Methionine sulfoximine (MSX), 100 mg 91016-100MG Carbamazepine, 1.0 mg/mL C-053 L-Phenylalanine, 100 mg 40541-100MG Carbamazepine-D10, 100 µg/mL C-094 L-Proline, 100 mg 93693-100MG Carbamazepine-10,11-epoxide, 1.0 mg/mL C-121 L-Serine, 100 mg 54763-100MG 13 Carbamazepine-10,11-epoxide- C6, 100 µg/mL C-128 L-Threonine, 100 mg 61506-100MG 13 Carbamazepine- C6, 100 µg/mL C-136 L-Tryptophan, 100 mg 51145-100MG 10,11-Dihydro-10-Hydroxycarbamazepine, D-091 L-Tyrosine, 100 mg 91515-100MG 1.0 mg/mL 13 L-Valine, 100 mg 50848-100MG 10,11-Dihydro-10-Hydroxycarbamazepine- C6, D-104 100 µg/mL Taurine, 100 mg 93019-100MG Felbamate, 2.0 mg/mL F-029 Analgesics Gabapentin, 1.0 mg/mL G-007 Acetaminophen, 1.0 mg/mL A-064 Gabapentin, 10 mg/mL G-021 Acetaminophen-D4, 100 µg/mL P-909 Gabapentin-D10, 1.0 mg/mL G-017 Acetaminophen-D4, 1.0 mg/mL P-917 Gabapentin-13C , 100 µg/mL G-018 Salicylic acid, 1.0 mg/m S-019 3 Gabapentin-D10, 100 µg/mL G-901 Salicylic acid-D4, 100 µg/mL S-042 Lamotrigine, 1.0 mg/mL L-019 Antibiotics Levetiracetam, 1.0 mg/mL L-020 Metronidazole-D3, 1.0 mg/mL M-184 Lamotrigine-13C,15N , 500 µg/mL L-022 AMOZ, 50 mg 93485-50MG 4 Levetiracetam-D , 100 µg/mL L-023 Anhydrotetracycline, 10 mg 94664-10MG 6 Lacosamide-13C,D , 100 µg/mL L-027 Benzbromarone, 50 mg 09147-50MG 3 Lacosamide, 1.0 mg/mL L-029 Chloramphenicol, 50 mg 75565-50MG Levetiracetam-D , 1.0 mg/mL L-031 Isoniazid, 50 mg 75182-50MG 6 Lacosamide-13C,D , 1.0 mg/mL L-032 Metronidazole, 50 mg 16677-50MG 3 Oxcarbazepine, 1.0 mg/mL O-025 Sulfadiazine, 100 mg 73901-100MG Oxcarbazepine-13C , 100 µg/mL O-039 Sulfadoxin, 100 mg 74627-100MG 6 Phenobarbital-D5 (deuterium label on side chain), P-004 Sulfamethoxazole, 100 mg 76177-100MG 100 µg/mL Tamoxifen, 50 mg 06734-50MG Phenobarbital, 1.0 mg/mL P-008 Trimethoprim, 100 mg 16967-100MG For more information or to order, visit SigmaAldrich.com 3 Quality For Life Product Description Cat. No. Product Description Cat. No. Anticonvulsants/Antiepileptics (Continued) Tetracyclic Antidepressants (Continued) Phenobarbital-D5 (deuterium label on side chain), P-017 Mianserin-D3, 100 µg/mL M-901 1.0 mg/mL Mianserin hydrochloride, 100 µg/mL M-919 Phenobarbital-D5 (deuterium label on ring), P-018 100 µg/mL Mirtazapine-D3, 100 µg/mL M-191 8-Methoxyloxapine, 25 mg B120031-25 Phenobarbital-D5 (deuterium label on ring), P-019 1.0 mg/mL N-Desmethylmirtazapine, 1.0 mg/mL D-086 Phenytoin, 1.0 mg/mL P-063 Mirtazapine, 1.0 mg/mL M-128 Pregabalin, 1.0 mg/mL P-066 Tricyclic Antidepressants Pregabalin, 10 mg/mL P-120 Amitriptyline-D3 HCl, 100 µg/mL A-085 Phenytoin-D10, 100 µg/mL P-067 Amitriptyline-D3 HCl, 1.0 mg/mL A-121 Pregabalin-D6, 100 µg/mL P-072 Amitriptyline HCl, 1.0 mg/mL A-923 Pregabalin-D6, 1.0 mg/mL P-096 Amitriptyline N-β-D-glucuronide, 100 µg/mL A-128-1ML 13 Pregabalin- C3, 100 µg/mL P-106 Clomipramine-D3 HCl, 100 µg/mL C-116 Retigabine, 1.0 mg/mL R-018 Clomipramine HCl, 1.0 mg/mL C-118 Retigabine-D4, 100 µg/mL R-019 Desmethyldoxepin (cis/trans), 1.0 mg/mL D-007 Rufinamide, 1.0 mg/mL R-023 Doxepin-D3 HCl (cis/trans), 100 µg/mL D-060 Tiagabine HCl, 1.0 mg/mL T-081 N-Desmethyldoxepin-D3 HCl (cis/trans), D-075 100 µg/mL Tiagabine-D6 HCl, 100 µg/mL T-082 Topiramate, 1.0 mg/mL T-039 Doxepin-D3 HCl (cis/trans), 1.0 mg/mL D-115 Doxepin HCl, 1.0 mg/mL D-927 Topiramate-D12, 100 µg/mL T-041 Valproic acid, 1.0 mg/mL V-006 Desipramine-D3 HCl, 1.0 mg/mL D-116 Desipramine-D3 HCl, 100 µg/mL D-903 Valproic Acid-D6, 1.0 mg/mL V-029 Vigabatrin, 1.0 mg/mL V-022 Desipramine HCl, 1.0 mg/mL D-906 Zonisamide, 1.0 mg/mL Z-005 Lofepramine HCl, 1.0 mg/mL L-041 13 N-Desmethylclomipramine-D3 HCl, 100 µg/mL D-113 Zonisamide- C6, 100 µg/mL Z-006 Antidepressants N-Desmethylclomipramine HCl, 100 µg/mL D-916 Buspirone HCl, 1.0 mg/mL B-054 N-Desmethyltrimipramine-D3 HCl, 100 µg/mL D-114 N-Desmethyltrimipramine maleate, 1.0 mg/mL D-920 Buspirone-D8 HCl, 100 µg/mL B-055 SNRI & SARI Nortriptyline-D3 HCl, 1.0 mg/mL N-090 Citalopram HBr, 100 µg/mL C-057 Imipramine HCl, 1.0 mg/mL I-902 Citalopram HBr, 1.0 mg/mL C-095 Imipramine-D3 maleate, 100 µg/mL I-903 Nortriptyline-D3 HCl, 100 µg/mL N-902 Citalopram-D6 HBr, 100 µg/mL C-090 N-Desmethylcitalopram HCl, 1.0 mg/mL D-047 Nortriptyline HCl, 1.0 mg/mL N-907 Trimipramine-D3 maleate, 100 µg/mL T-071 N-Desmethylcitalopram-D3 HCl, 100 µg/mL D-074 Trimipramine, 1.0 mg/mL T-904 Fluoxetine-D6 Oxalate, 1.0 mg/mL F-038 Fluoxetine HCl, 1.0 mg/mL F-918 Antifungals 5-Fluorocytosine, 2.0 mg/mL F-030 Fluoxetine-D6 Oxalate, 100 µg/mL F-919 Fluconazole, 2.0 mg/mL F-031 Norfluoxetine-D6 Oxalate, 1.0 mg/mL N-102 13 Norfluoxetine Oxalate, 1.0 mg/mL N-923 Fluconazole- C3, 1.0 mg/m F-035 Hydroxyitraconazole, 100 µg/mL H-110 Norfluoxetine-D6 Oxalate, 100 µg/mL N-922 mCPP HCl, 1.0 mg/mL C-089 Hydroxyitraconazole-D4, 100 µg/mL H-111 Ketoconazole, 2.0 mg/mL K-004 mCPP-D8 HCl, 100 µg/mL C-112 Trazodone HCl, 1.0 mg/mL T-030 Ketoconazole-D4, 1.0 mg/mL K-005 Itraconazole, 2.0 mg/mL I-015 Trazodone-D6 HCl, 100 µg/mL T-079 (±)-O-Desmethylvenlafaxine, 1.0 mg/mL V-045 Posaconazole, 2.0 mg/mL P-103 Tetracyclic Antidepressants Posaconazole-D4, 1.0 mg/mL P-108 Amoxapine, 1.0 mg/mL A-123 Voriconazole, 2.0 mg/mL V-032 8-Hydroxy Amoxapine, 1.0 mg/mL H-118-1ML Voriconazole-D3, 1.0 mg/mL V-036 Maprotiline HCl, 1.0 mg/mL M-920 To order, visit SigmaAldrich.com 4 Product Description Cat. No. Product Description Cat. No. Antipsychotics Bile Acids (Continued) Aripiprazole-D8, 100 µg/mL A-081 Chenodeoxycholic acid-D4, 100 µg/mL C-147 Aripiprazole, 1.0 mg/mL A-119 Cholic acid-D4, 100 µg/mL C-148 Clozapine, 1.0 mg/mL C-059 Deoxycholic acid, 500 µg/mL D-126 Clozapine-D4, 100 µg/mL C-091 Deoxycholic acid-D4, 100 µg/mL D-127 Clozapine N-oxide, 100 µg/mL C-125 Lithocholic acid, 50 µg/mL L-042 N-Desmethylclozapine, 1.0 mg/mL D-048 Taurocholic acid sodium salt, 500 µg/mL T-110 (as free sulfate) Dehydro Aripiprazole, 1.0 mg/mL D-053 Ursodeoxycholic acid, 500 µg/mL U-001 Desmethylolanzapine dihydrochloride, 1.0 mg/mL D-069 Ursodeoxycholic acid-D4, 100 µg/mL U-002 N-Desmethylolanzapine-D8 dihydrochloride, D-070 100 µg/mL Caffeine-Related Drugs Fluphenazine diHCl, 1.0 mg/mL F-903 Caffeine, 1.0 mg/mL C-051 Haloperidol-D4, 100 µg/mL H-002 Caffeine-13C3, 1.0 mg/mL C-082 Haloperidol, 1.0 mg/mL H-030 Theophylline, 1.0 mg/mL IMPC-051-01 7-Hydroxyquetiapine, 1.0 mg/mL H-081 Cardiac Drugs 9-Hydroxyrisperidone, 1.0 mg/mL H-076 Atropine, 1.0 mg/mL A-046 9-Hydroxyrisperidone-D4, 100 µg/mL H-095 Amiodarone HCl, 1.0 mg/mL A-060 Hydroxy Iloperidone, 100 µg/mL H-104 Amiodarone-D4 HCl, 100 µg/mL A-083 Iloperidone, 1.0 mg/mL I-011 Atenolol, 1.0 mg/mL A-072 13 Iloperidone- C,D3, 100 µg/mL I-013 Clonidine, 1.0 mg/mL C-033 Lurasidone HCl, 1.0 mg/mL L-030 Clonidine-D4 HCl, 100 µg/mL C-157 Lurasidone-D8 HCl, 100 µg/mL L-035 Digitoxin, 1.0
Load more

Recommended publications
  • Diphenhydramine Hydrochloride (CASRN 147-24-0) in F344/N Rats
    NATIONAL TOXICOLOGY PROGRAM Technical Report Series No. 355 TOXICOLOGY AND CARCINOGENESIS STUDIES OF DIPHENHYDRAMINE HYDROCHLORIDE (CAS NO. 147-24-0) IN F344/N RATS AND B6C3F1 MICE (FEED STUDIES) LJ.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health NTP ‘TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF DIPHENHYDRAMINE HYDROCHLORIDE (CAS NO. 147-24-0) IN F344/N RATS AND B6C3F1 MICE (FEED STUDIES) R. Melnick, Ph.D., Study Scientist NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709 September 1989 NTP TR 355 NIH Publication No. 89-2810 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health CONTENTS PAGE ABSTRACT ................................................................ 3 EXPLANATION OF LEVELS OF EVIDENCE OF CARCINOGENIC ACTIVITY .................. 6 CONTRIBUTORS ............................................................ 7 PEERREVIEWPANEL ........................................................ 8 SUMMARY OF PEER REVIEW COMMENTS ......................................... 9 I. INTRODUCTION ........................................................ 11 I1. MATERIALS AND METHODS .............................................. 21 III. RESULTS ............................................................. 35 RATS ............................................................. 36 MICE ............................................................. 45 GENETIC TOXICOLOGY ............................................... 53 IV.
    [Show full text]
  • Role of Dietary Histidine in the Prevention of Obesity and Metabolic Syndrome
    Open access Editorial Open Heart: first published as 10.1136/openhrt-2017-000676 on 1 July 2018. Downloaded from Role of dietary histidine in the prevention of obesity and metabolic syndrome James J DiNicolantonio,1 Mark F McCarty,2 James H OKeefe 1 To cite: DiNicolantonio JJ, HISTIDINE SUPPLEMENTATION AMELIORATES histidine dose dependently increases hypo- McCarty MF, OKeefe JH. Role of METABOLIC SYNDROME thalamic levels of histamine as well as hypo- dietary histidine in the prevention of obesity and A recent Chinese supplementation study, in thalamic activity of histidine decarboxylase, metabolic syndrome. Open Heart which obese middle-aged women diagnosed the enzyme which converts histidine to hista- 10 2018;5:e000676. doi:10.1136/ with metabolic syndrome received 12 weeks mine. Such administration also inhibits food openhrt-2017-000676 of supplemental histidine (2 g, twice daily) or consumption—an effect that is blocked in matching placebo, achieved remarkable find- animals pretreated with an irreversible inhib- 1 Accepted 24 April 2018 ings. Insulin sensitivity improved significantly itor of histidine decarboxylase. in the histidine-supplemented subjects, and Neuronal histamine release in the hypo- this may have been partially attributable to thalamus is subject to feedback regulation loss of body fat. Body mass index (BMI), waist by presynaptic H3 receptors. In rodent circumference and body fat declined in the studies, antagonists and inverse agonists for histidine-supplemented group relative to the these receptors have been shown to mark- placebo group; the average fat loss in the histi- edly amplify hypothalamic histamine levels, dine group was a robust 2.71 kg. Markers of suppress feeding, decrease body weight and systemic inflammation such as serum tumour enhance metabolic rate.11–15 Such agents may necrosis factor-alpha (TNF-α) and inter- have clinical potential for managing obesity.
    [Show full text]
  • Dynamic Regulation of Synaptic GABA Release by the Glutamate-Glutamine Cycle in Hippocampal Area CA1
    The Journal of Neuroscience, August 16, 2006 • 26(33):8537–8548 • 8537 Development/Plasticity/Repair Dynamic Regulation of Synaptic GABA Release by the Glutamate-Glutamine Cycle in Hippocampal Area CA1 Shu-Ling Liang,1 Gregory C. Carlson,1 and Douglas A. Coulter1,2 1Division of Neurology and the Pediatric Regional Epilepsy Program, Children’s Hospital of Philadelphia, and 2Departments of Pediatrics, Neurology, and Neuroscience, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 Vesicular GABA and intraterminal glutamate concentrations are in equilibrium, suggesting inhibitory efficacy may depend on glutamate availability. Two main intraterminal glutamate sources are uptake by neuronal glutamate transporters and glutamine synthesized through the astrocytic glutamate-glutamine cycle. We examined the involvement of the glutamate-glutamine cycle in modulating GABAergic synaptic efficacy. In the absence of neuronal activity, disruption of the glutamate-glutamine cycle by blockade of neuronal glutamine transport with ␣-(methylamino) isobutyric acid (MeAIB; 5 mM) or inhibition of glutamine synthesis in astrocytes with methionine sulfoximine (MSO; 1.5 mM) had no effect on miniature IPSCs recorded in hippocampal area CA1 pyramidal neurons. How- ever, after a period of moderate synaptic activity, application of MeAIB, MSO, or dihydrokainate (250 ␮M; an astrocytic glutamate transporter inhibitor) significantly reduced evoked IPSC (eIPSC) amplitudes. The MSO effect could be reversed by exogenous application of glutamine (5 mM), whereas glutamine could not rescue the eIPSC decreases induced by the neuronal glutamine transporter inhibitor MeAIB. The activity-dependent reduction in eIPSCs by glutamate-glutamine cycle blockers was accompanied by an enhanced blocking effect of the low-affinity GABAA receptor antagonist, TPMPA [1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid], consistent with diminished GABA release.
    [Show full text]
  • Methionine Sulfoximine: a Novel Anti Inflammatory Agent
    Wayne State University Wayne State University Dissertations January 2018 Methionine Sulfoximine: A Novel Anti Inflammatory Agent Tyler Peters Wayne State University, [email protected] Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations Part of the Biochemistry Commons Recommended Citation Peters, Tyler, "Methionine Sulfoximine: A Novel Anti Inflammatory Agent" (2018). Wayne State University Dissertations. 2124. https://digitalcommons.wayne.edu/oa_dissertations/2124 This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. METHIONINE SULFOXIMINE: A NOVEL ANTI-INFLAMMATORY AGENT by TYLER J. PETERS DISSERTATION Submitted to the Graduate School of Wayne State University – School of Medicine Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOHPY 2018 MAJOR: BIOCHEMISTRY & MOL. BIOLOGY Approved By: __________________________________________ Advisor Date DEDICATION This work is dedicated to my family. I wouldn’t have made it this far without your unconditional love and support. ii ACKNOWLEDGEMENTS Thank you Dr. Brusilow, I consider myself very fortunate for having the privilege of working in the laboratory of Dr. William S.A. Brusilow these past few years. Under his mentorship, my scientific autonomy was always respected, and my opinions were always valued with consideration. I am thankful for his guidance and support as an advisor; I truly admire his patience and envy his calm demeanor. He exemplifies scientific integrity, and his dedication to develop MSO has inspired me. I had never experienced consistent failure in any aspect of life before encountering scientific research; at times I felt that Dr.
    [Show full text]
  • Glutamate and GABA Dynamics in Early Ischaemia of Rat
    J. Physiol. (2002). 543.P Research Symposium – Mechanisms of Ischaemic Cell Death 25S ATP occurring in ischaemia may prevent a protective uptake of glutamate into glia in early ischaemia: with glutamine synthetase Glutamate and GABA dynamics in early ischaemia of rat inhibited, uptake of only a little glutamate released from neurons hippocampal slices may be sufficient to raise [glutamate]i in glia sufficiently to D. Attwell, N.J. Allen, M. Hamman and D.J. Rossi inhibit further uptake. Department of Physiology, University College London, Gower Street, Hamann, M. et al. (2002). Eur. J. Neurosci. 15, 308–314. London WC1E 6BT, UK Rossi, D.J. et al. (2000). Nature 403, 316–321. During brain ischaemia, the run-down of transmembrane ion gradients caused by the fall of ATP levels occurring leads to a rise This work was supported by The Wellcome Trust. in extracellular glutamate and GABA concentrations. The rise of glutamate concentration triggers neuronal death. In simulated All procedures accord with current local guidelines. ischaemia of hippocampal slices, taken from rats humanely killed in accordance with UK animal use legislation, we have used receptors in whole-cell patch-clamped CA1 pyramidal cells to sense released glutamate and GABA. ECl was set to 0 mV, so that currents mediated by ionotropic GABA receptors were inward, Cation channels: a radical way of killing cells and membrane current was recorded at _30 mV to allow glutamate sensing by NMDA and AMPA receptors. Mike Ashford On applying superfusion solution mimicking the energy University of Dundee deprivation occurring during severe ischaemia (no oxygen and glucose, cyanide and iodoacetate present), a slow small increase of inward current occurred over the first few minutes, followed by a sudden massive inward current (nanoamps) which then sagged back to a less inward plateau (Rossi et al.
    [Show full text]
  • Aldrich Raman
    Aldrich Raman Library Listing – 14,033 spectra This library represents the most comprehensive collection of FT-Raman spectral references available. It contains many common chemicals found in the Aldrich Handbook of Fine Chemicals. To create the Aldrich Raman Condensed Phase Library, 14,033 compounds found in the Aldrich Collection of FT-IR Spectra Edition II Library were excited with an Nd:YVO4 laser (1064 nm) using laser powers between 400 - 600 mW, measured at the sample. A Thermo FT-Raman spectrometer (with a Ge detector) was used to collect the Raman spectra. The spectra were saved in Raman Shift format. Aldrich Raman Index Compound Name Index Compound Name 4803 ((1R)-(ENDO,ANTI))-(+)-3- 4246 (+)-3-ISOPROPYL-7A- BROMOCAMPHOR-8- SULFONIC METHYLTETRAHYDRO- ACID, AMMONIUM SALT PYRROLO(2,1-B)OXAZOL-5(6H)- 2207 ((1R)-ENDO)-(+)-3- ONE, BROMOCAMPHOR, 98% 12568 (+)-4-CHOLESTEN-3-ONE, 98% 4804 ((1S)-(ENDO,ANTI))-(-)-3- 3774 (+)-5,6-O-CYCLOHEXYLIDENE-L- BROMOCAMPHOR-8- SULFONIC ASCORBIC ACID, 98% ACID, AMMONIUM SALT 11632 (+)-5-BROMO-2'-DEOXYURIDINE, 2208 ((1S)-ENDO)-(-)-3- 97% BROMOCAMPHOR, 98% 11634 (+)-5-FLUORODEOXYURIDINE, 769 ((1S)-ENDO)-(-)-BORNEOL, 99% 98+% 13454 ((2S,3S)-(+)- 11633 (+)-5-IODO-2'-DEOXYURIDINE, 98% BIS(DIPHENYLPHOSPHINO)- 4228 (+)-6-AMINOPENICILLANIC ACID, BUTANE)(N3-ALLYL)PD(II) CL04, 96% 97 8167 (+)-6-METHOXY-ALPHA-METHYL- 10297 ((3- 2- NAPHTHALENEACETIC ACID, DIMETHYLAMINO)PROPYL)TRIPH 98% ENYL- PHOSPHONIUM BROMIDE, 12586 (+)-ANDROSTA-1,4-DIENE-3,17- 99% DIONE, 98% 13458 ((R)-(+)-2,2'- 963 (+)-ARABINOGALACTAN BIS(DIPHENYLPHOSPHINO)-1,1'-
    [Show full text]
  • Convenient Preparation of Poly(L-Histidine) by the Direct Polymerization of L-Histidine Or Nim Benzyl-L-Histidine with Diphenylphosphoryl Azide
    Polymer Journal, Vol. 13, No. 12, pp 1151-1154 (1981) SHORT COMMUNICATION Convenient Preparation of Poly(L-histidine) by the Direct Polymerization of L-Histidine or Nim_Benzyl-L-histidine with Diphenylphosphoryl Azide Takumi NARUSE, Bun-ichiro NAKAJIMA, Akihiro TSUTSUMI, and Norio NISHI Department of Polymer Science, Faculty of Science, Hokkaido University, Nishi 8-chome, Kita 10-jo, Kita-ku, Sapporo 060, Japan. (Received August 14, 1981) KEY WORDS Polymerization I Diphenylphosphoryl Azide (DPPA) I L- Histidine I N'm-Benzyl-L-histidine I Poly(L-histidine) I Poly(N'm-benzyl-L­ histidine) I IR Spectrum I 13C NMR Spectrum I Intrinsic Viscosity I Poly(L-histidine) is a very interesting poly(a­ histidine) by the polymerization of L-histidine with amino acid) as a synthetic functional polymer or as iodine-phosphonic acid esters was unsuccessful. The a model for the functional biopolymer such as simplification of the synthetic route for poly(L­ enzymes. It is known, however, that poly(L­ histidine) is still necessary. histidine) can not be prepared by the Fuchs­ Diphenylphosphoryl azide (DPPA) has been used Farthing method 1 which is very popular for prepar­ as a convenient reagent for racemization-free pep­ ing poly(a-amino acid)s. A synthetic route with tide synthesis, since it was synthesized by Shioiri et several steps involving the synthesis of NCA (a­ a!. in 1972.6 Recently, we reported that this reagent amino acid N-carboxyanhydride) by the rather can also be used successfully for the polymerization classical Leuchs method/ have been used for the of amino acids or peptides.
    [Show full text]
  • Title Structure of the Human Histamine H1 Receptor Complex With
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Kyoto University Research Information Repository Structure of the human histamine H1 receptor complex with Title doxepin. Shimamura, Tatsuro; Shiroishi, Mitsunori; Weyand, Simone; Tsujimoto, Hirokazu; Winter, Graeme; Katritch, Vsevolod; Author(s) Abagyan, Ruben; Cherezov, Vadim; Liu, Wei; Han, Gye Won; Kobayashi, Takuya; Stevens, Raymond C; Iwata, So Citation Nature (2011), 475(7354): 65-70 Issue Date 2011-07-07 URL http://hdl.handle.net/2433/156845 © 2011 Nature Publishing Group, a division of Macmillan Right Publishers Limited. Type Journal Article Textversion author Kyoto University Title: Structure of the human histamine H1 receptor in complex with doxepin. Authors Tatsuro Shimamura 1,2,3*, Mitsunori Shiroishi 1,2,4*, Simone Weyand 1,5,6, Hirokazu Tsujimoto 1,2, Graeme Winter 6, Vsevolod Katritch7, Ruben Abagyan7, Vadim Cherezov3, Wei Liu3, Gye Won Han3, Takuya Kobayashi 1,2‡, Raymond C. Stevens3‡and So Iwata1,2,5,6,8‡ 1. Human Receptor Crystallography Project, ERATO, Japan Science and Technology Agency, Yoshidakonoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. 2. Department of Cell Biology, Graduate School of Medicine, Kyoto University, Yoshidakonoe-cho, Sakyo-Ku, Kyoto 606-8501, Japan. 3. Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. 4. Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. 5. Division of Molecular Biosciences, Membrane Protein Crystallography Group, Imperial College, London SW7 2AZ, UK. 6. Diamond Light Source, Harwell Science and Innovation Campus, Chilton, Didcot, Oxfordshire OX11 0DE, UK.
    [Show full text]
  • Differential Pulse Polarographic Study of Simple and Mixed Complexes of Copper Ions with the Antidepressant Drug Imipramine and Glutamic Acid Or Histidine
    Differential Pulse Polarographic Study of Simple and Mixed Complexes of Copper Ions with the Antidepressant Drug Imipramine and Glutamic Acid or Histidine M. KHODARI Department of Chemistry, Faculty of Science, South Valley University, Qena, Egypt Received 12 May 1997 The formation of binary and ternary complexes of glutamic acid or histidine and imipramine with Cu(II) has been examined using differential pulse Polarographie technique. The reduction of both simple and mixed systems is reversible and controlled by diffusion. The obtained results reveal the formation of mixed complexes. For the system Cu—Glu—Imip, one mixed complex was formed: Cu(Glu)(Imip)2 with stability constant log{/3i2} = 10.51, while the system Cu—His— Imip forms two complexes Cu(His)(Imip) and Cu(His)(Imip)2 with stabilities log{/?n} = 6.25 and log{/?i2} = 8.77, respectively. These experimental values were compared with the statistical ones. Mixed complexes are usually formed when the Histidine and other amino acids are involved in metal ion is present in a mixture of two or more com- copper(II) transport in blood and exchange interac­ plexing species in solution [1—3]. Different electro­ tions with serum albumin [13]. Imipramine is one of chemical techniques were applied to study such sys­ the most widely used drugs for the treatment of de­ tems [4—6]. The method of DeFord and Hume [7] as pression [14]. Hence their binary and ternary com­ extended by Schaap and McMasters [1] was used to plexes are of great interest. So the present work is calculate the formation constants of the mixed system aimed to study the expected formed complexes be­ using direct current Polarographie technique.
    [Show full text]
  • Analytical Method Developments of Antibody Drug Conjugates And
    Analytical method developments of antibody drug conjugates and disease biomarkers in microdialysis samples By Yunan Wang Submitted to the graduate degree program in Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. ________________________________ Chairperson Dr. Susan Lunte ________________________________ Dr. Heather Desaire ________________________________ Dr. Julie Stenken ________________________________ Dr. Robert Dunn ________________________________ Dr. Zhuo Wang Date Defended: January 27th, 2016 The Dissertation Committee for Yunan Wang certifies that this is the approved version of the following dissertation: Analytical method developments of antibody drug conjugates and disease biomarkers in microdialysis samples ________________________________ Chairperson Dr. Susan Lunte Date approved: February 1st, 2016 ii Abstract This dissertation focuses on developing analytical methods to study biomarkers in different pharmaceutical samples. Three different analytical methods were developed for microdialysis samples and antibody drug conjugates as anti-tumor drug. The first part of this dissertation is to develop a capillary electrophoresis with laser induced fluorescence (CE-LIF) method to monitor the change of amino acids in rat brain microdialysate as biomarkers of oxidative stress in epileptic seizures. Ornithine and citrulline was successfully separated and quantified. 3-Mercaptopropionic acid (3- MPA) was administrated to rat brain hippocampus region as a convulsant to induce epileptic seizures to free-moving rats. An increase of citrulline and ornithine level was observed after the seizure, and this confirmed nitric oxide were produced in epileptic seizures. In the second project, a high-performance liquid chromatography with mass spectrometry (HPLC-MS) method is developed to simultaneously monitor the change of 13 eicosanoids as biomarkers in rat colon microdialysate to study the enzymatic pathways of inflammatory bowel disease.
    [Show full text]
  • Identification of Histidine at the Catalytic Site of the Photosynthetic
    Proc. Natl. Acad. Sci. USA Vol. 91, pp. 704-708, January 1994 Biophysics Identification of histidine at the catalytic site of the photosynthetic oxygen-evolving complex (histidine labeling/pulsed electron paramagnetic resonance/manganese/photosystem II) XIAO-SONG TANG*, BRUCE A. DINER*, BARBARA S. LARSEN*, M. LANE GILCHRIST, JR.t, GARY A. LORIGANt, AND R. DAVID BRITTt *Central Research and Development Department, Experimental Station, P.O. Box 80173, E.I. DuPont de Nemours and Company, Wilmington, DE 19880; and tDepartment of Chemistry, University of California, Davis, CA 95616 Communicated by Pierre Joliot, October 26, 1993 (received for review September 13, 1993). ABSTRACT The molecular oxygen in our atmosphere is a nitrogen site. Electron-nuclear double resonance (ENDOR) product of a water-splitting reaction that occurs in the oxygen- studies of a thermophilic cyanobacterium grown on 15NO3 evolving complex ofphotosystem II ofoxygenic photosynthesis. showed 15N ENDOR transitions in the range 1-4 MHz (14). The catalytic core of the oxygen-evolving complex Is an ensem- These 15N ENDOR transitions most likely arise from the ble of four manganese atoms arranged in a cluster of undeter- same nitrogen class or classes that give rise to the 14N mined structure. The pulsed electron paramagnetic resonance ESEEM peaks. Neither the ESEEM nor the ENDOR exper- (EPR) technique of electron spin-echo envelope modulation iments provide a definitive chemical assignment to the origin (ESEEM) can be used to measure nuclear spin transitions of of the nitrogen spin transitions. To assign the origin of these nuclei magnetically coupled to paramagnetic metal centers of nitrogen spin transitions, we have incorporated into the PSII enzymes.
    [Show full text]
  • Study Protocol and Amendments As Applicable  Obtaining Signed Informed Consent  Investigator Reporting Requirements (E.G
    2016 N270529_06 C ONFIDENTIA L The GlaxoS mith Kline group of co mpanies 205722 TI T L E P A G E Di visi o n: W orl d w ide Develop ment Infor mation Type: Protocol A mend ment Titl e: A rando mised double -bli n d (s p o ns or o p e n), pl a c e b o c o ntr oll e d, si n gl e as c e n di n g d os e, First Ti m e i n H u m a n st u d y i n p arti ci p a nts wit h mil d t o m o d er at e ast h m a t o ass ess s af et y, t ol er a bilit y , i m munogenicity, phar macokinetics and phar macodyna mics of GS K3511294 ad ministered subcutaneousl y. Co mpound Nu mber: GS K3511294 Develop ment Phase: I Effective Date: 0 7- J A N -2019 Protocol A mend ment Nu mber: 0 6 A ut hor (s) : P P D P P D P P D Copy ri g ht 2 0 1 8 t h e Gl a x o S mit h Kli n e gr o u p of c o m p a ni es. All ri g hts r es er v e d. Unauthorised cop yi n g or us e of t his i nf or m ati o n is pr o hi bit e d.
    [Show full text]